--- title: "賽諾菲：藥物 SAR446597 已獲得 FDA 快速通道資格認定" description: "7 月 16 日，賽諾菲發表聲明稱，美國食品藥品監督管理局已授予 SAR446597 快速通道資格認定，該藥物是一種一次性玻璃體內基因療法，用於治療年齡相關性黃斑變性引起的地圖樣萎縮。快速通道資格認定流程旨在促進治療嚴重疾病和填補未滿足醫療需求的藥物開發並加快其審評。FDA 設立這一程序旨在幫助患者更早獲得重要新藥，其適用範圍涵蓋多種嚴重疾病。" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/248820917.md" published_at: "2025-07-16T14:14:02.000Z" --- # 賽諾菲：藥物 SAR446597 已獲得 FDA 快速通道資格認定 > 7 月 16 日，賽諾菲發表聲明稱，美國食品藥品監督管理局已授予 SAR446597 快速通道資格認定，該藥物是一種一次性玻璃體內基因療法，用於治療年齡相關性黃斑變性引起的地圖樣萎縮。快速通道資格認定流程旨在促進治療嚴重疾病和填補未滿足醫療需求的藥物開發並加快其審評。FDA 設立這一程序旨在幫助患者更早獲得重要新藥，其適用範圍涵蓋多種嚴重疾病。 7 月 16 日，賽諾菲發表聲明稱，美國食品藥品監督管理局已授予 SAR446597 快速通道資格認定，該藥物是一種一次性玻璃體內基因療法，用於治療年齡相關性黃斑變性引起的地圖樣萎縮。快速通道資格認定流程旨在促進治療嚴重疾病和填補未滿足醫療需求的藥物開發並加快其審評。FDA 設立這一程序旨在幫助患者更早獲得重要新藥，其適用範圍涵蓋多種嚴重疾病。 ### Related Stocks - [SNYNF.US - 賽諾菲](https://longbridge.com/zh-HK/quote/SNYNF.US.md) - [SNY.US - 賽諾菲集團](https://longbridge.com/zh-HK/quote/SNY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | What To Expect From Analog Devices’s (ADI) Q4 Earnings | Analog Devices (ADI) will report Q4 earnings this Wednesday. Last quarter, it exceeded revenue expectations by 2.1%, wit | [Link](https://longbridge.com/zh-HK/news/276090818.md) | | Artisan Partners Ltd Partnership Discloses 10.11% Stake In Pearson As Of 11 Feb, Says Filing | Pearson PLC :PEARSON PLC - HOLDING(S) IN COMPANYARTISAN PARTNERS LIMITED PARTNERSHIP DISCLOSES 10.11% STAKE IN PEARSON A | [Link](https://longbridge.com/zh-HK/news/276068264.md) | | REG - RELX PLC - Director/PDMR Shareholding | RELX PLC announced changes in director shareholdings. CEO Erik Engstrom increased his holdings to 1,327,129 shares, whil | [Link](https://longbridge.com/zh-HK/news/276101908.md) | | 03:00 ETSéptima edición del Concurso S.Pellegrino Young Chef Academy | S.Pellegrino has announced the launch of the seventh edition of the S.Pellegrino Young Chef Academy Competition, aimed a | [Link](https://longbridge.com/zh-HK/news/276041621.md) | | Sanofi: Beyfortus Study Shows Benefit For Infants Beyond First RSV Season | Sanofi announced that a study on its RSV immunization program using Beyfortus showed a significant reduction in RSV-rela | [Link](https://longbridge.com/zh-HK/news/276038221.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。